Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor

被引:18
|
作者
Liu, An [1 ]
Dong, Lei [1 ,3 ]
Wei, Xiao-Li [2 ]
Yang, Xiao-Hong [1 ]
Xiao, Jun-Hai [2 ]
Liu, Zai-Qun [4 ]
机构
[1] Jilin Univ, Sch Pharmaceut Sci, Changchun 130021, Peoples R China
[2] Beijing Inst Pharmacol & Toxicol, Lab Comp Aided Drug Design & Discovery, Beijing 100850, Peoples R China
[3] Jilin Univ, Affiliated Hosp 1, Changchun 130021, Peoples R China
[4] Jilin Univ, Coll Chem, Dept Organ Chem, Changchun 130021, Peoples R China
关键词
Programmed cell death-1 (PD-1); Inhibitor; Resorcinol; 3-Hydroxythiophenol; LUNG-CANCER; BLOCKADE; THERAPY; PATHWAY; ANTIBODIES; ANTITUMOR; SAFETY; AGENTS;
D O I
10.1016/j.ejps.2016.03.023
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Blockading the interaction of programmed death-1 (PD-1) protein with its ligands (PD-Ls, such as PD-L1) was proved to be a pathway for suppressing the development of tumors and other degradations of biological species. Thus, finding PD-1 inhibitors situated at the convergence point of drug discovery. In addition to some monoclonal antibodies applied to treat cancers clinically, the screening of organic molecules for hindering the interaction of PD-1 with PD-L1 became an efficient strategy in the development of PD-1 inhibitors. Weherein applied resorcinol and 3-hydroxythiophenol as the core to link with N, N-dimethylcarbamate and other alkyl-substituted amines to afford 13 amine-appended phenyl dimethylcarbamates (AAPDs). The test for blockading the combination of PD-1 with PD-L1 revealed that abilities of 13 AAPDs were higher than that of sulfamethizole, a successful PD-1 inhibitor. In particular, large hydrophobic substituents at amine moiety or a nitro at resorcinol skeleton enhanced the inhibitory effect of AAPD even higher than that of sulfamethoxypyridazine, another successful PD-1 inhibitor. The present results may provide valuable information for further investigation on synthetic PD-1 inhibitors. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:50 / 58
页数:9
相关论文
共 50 条
  • [1] Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
    Guo, Liting
    Zhang, Haijun
    Chen, Baoan
    JOURNAL OF CANCER, 2017, 8 (03): : 410 - 416
  • [2] Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
    Justin C. Kao
    Adipong Brickshawana
    Teerin Liewluck
    Current Neurology and Neuroscience Reports, 2018, 18
  • [3] Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
    Kao, Justin C.
    Brickshawana, Adipong
    Liewluck, Teerin
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2018, 18 (10)
  • [4] Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics
    Cassol, Clarissa A.
    Owen, Dwight
    Kendra, Kari
    Braga, Juarez R.
    Frankel, Wendy L.
    Arnold, Christina A.
    HISTOPATHOLOGY, 2020, 77 (02) : 240 - 249
  • [5] Programmed death-1 (PD-1) Expression in Sezary Syndrome
    Wehkamp, U.
    Oschlies, I
    Brasch, J.
    Klapper, W.
    Weichenthal, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 922 - 922
  • [6] Nivolumab-Induced Hepatitis: A Rare Side Effect of Programmed Cell Death-1 (PD-1) Inhibitor
    Kang, Gurjeet
    Ghanekar, Dilip
    Orpiano, Christopher L.
    Quinn, Michael
    Staffetti, Joseph
    Venu, Lakshminarasimhan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S1326 - S1327
  • [7] The Role of Programmed Cell Death-1 (PD-1) and Its Ligands in Pediatric Cancer
    van Dam, Laura S.
    de Zwart, Verena M.
    Meyer-Wentrup, Friederike A. G.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (02) : 190 - 197
  • [8] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN UTERINE CARCINOSARCOMAS
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1125 - 1125
  • [9] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN UTERINE CARCINOSARCOMAS
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 219 - 219
  • [10] Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells
    Mallett, Grace
    Laurence, Arian
    Amarnath, Shoba
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)